Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Drops By 65.4%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 130,300 shares, a decline of 65.4% from the August 15th total of 376,200 shares. Approximately 13.0% of the company’s shares are sold short. Based on an average daily volume of 192,400 shares, the days-to-cover ratio is presently 0.7 days.

Sonoma Pharmaceuticals Trading Down 2.1 %

SNOA traded down $0.07 during mid-day trading on Thursday, hitting $3.20. 33,339 shares of the stock were exchanged, compared to its average volume of 144,097. The firm’s fifty day moving average is $0.52 and its two-hundred day moving average is $0.19. Sonoma Pharmaceuticals has a 1-year low of $2.32 and a 1-year high of $20.40. The company has a market cap of $60.81 million, a PE ratio of -4.81 and a beta of 1.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.00 earnings per share (EPS) for the quarter. Sonoma Pharmaceuticals had a negative net margin of 35.91% and a negative return on equity of 65.66%. The company had revenue of $3.39 million for the quarter. As a group, research analysts anticipate that Sonoma Pharmaceuticals will post -4 earnings per share for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.